CN1484650B - 尿皮质素蛋白及其用途 - Google Patents

尿皮质素蛋白及其用途 Download PDF

Info

Publication number
CN1484650B
CN1484650B CN018157831A CN01815783A CN1484650B CN 1484650 B CN1484650 B CN 1484650B CN 018157831 A CN018157831 A CN 018157831A CN 01815783 A CN01815783 A CN 01815783A CN 1484650 B CN1484650 B CN 1484650B
Authority
CN
China
Prior art keywords
urocortin
dna
crf
related peptide
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN018157831A
Other languages
English (en)
Chinese (zh)
Other versions
CN1484650A (zh
Inventor
W·W·韦尔
P·F·索切纳科
K·A·刘易斯
J·M·沃恩
T·M·雷耶斯
J·E·沃恩
J·B·赫格埃施
M·H·佩林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RESEARCH DEVELOPMENT FOUDATION
Original Assignee
RESEARCH DEVELOPMENT FOUDATION
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RESEARCH DEVELOPMENT FOUDATION filed Critical RESEARCH DEVELOPMENT FOUDATION
Publication of CN1484650A publication Critical patent/CN1484650A/zh
Application granted granted Critical
Publication of CN1484650B publication Critical patent/CN1484650B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physics & Mathematics (AREA)
CN018157831A 2000-08-04 2001-07-31 尿皮质素蛋白及其用途 Expired - Fee Related CN1484650B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22325500P 2000-08-04 2000-08-04
US60/223,255 2000-08-04
US27396901P 2001-03-07 2001-03-07
US60/273,969 2001-03-07
PCT/US2001/023976 WO2002012307A1 (en) 2000-08-04 2001-07-31 Urocortin proteins and uses thereof

Publications (2)

Publication Number Publication Date
CN1484650A CN1484650A (zh) 2004-03-24
CN1484650B true CN1484650B (zh) 2012-12-12

Family

ID=26917597

Family Applications (1)

Application Number Title Priority Date Filing Date
CN018157831A Expired - Fee Related CN1484650B (zh) 2000-08-04 2001-07-31 尿皮质素蛋白及其用途

Country Status (16)

Country Link
US (4) US6838274B2 (enExample)
EP (1) EP1305334B1 (enExample)
JP (1) JP4873825B2 (enExample)
KR (1) KR100879232B1 (enExample)
CN (1) CN1484650B (enExample)
AT (1) ATE408622T1 (enExample)
AU (2) AU2001284683B2 (enExample)
CA (1) CA2418144C (enExample)
CY (1) CY1110424T1 (enExample)
DE (1) DE60135850D1 (enExample)
DK (1) DK1305334T3 (enExample)
ES (1) ES2313978T3 (enExample)
IL (2) IL154102A0 (enExample)
PT (1) PT1305334E (enExample)
RU (1) RU2278871C2 (enExample)
WO (1) WO2002012307A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL154102A0 (en) * 2000-08-04 2003-07-31 Res Dev Foundation Urocortin proteins and uses thereof
US20020082409A1 (en) 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
AU2002306853B2 (en) 2001-03-15 2006-07-06 Research Development Foundation Urocortin-III and uses thereof
US7192923B2 (en) 2002-01-16 2007-03-20 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
WO2008047241A2 (en) * 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
EP2522351B1 (en) 2007-06-13 2017-09-06 Research Development Foundation Treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling
EP2187924A2 (en) * 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Use of a peptide as a therapeutic agent
WO2009033807A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Therapeutic uses of b-type natriuretic peptide and human growth hormone 1-43
WO2011025905A1 (en) 2009-08-28 2011-03-03 Research Development Foundation Urocortin 2 analogs and uses thereof
WO2013063046A1 (en) 2011-10-24 2013-05-02 Research Development Foundation Methods for increasing insulin secretion by co-stimulation of corticotropin-releasing factor receptors
KR102107482B1 (ko) 2012-02-14 2020-05-08 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 심혈관 질환 및 다른 증상에 대한 파라크린 유전자의 전신 전달 및 조절 발현
JOP20170153A1 (ar) * 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
WO2020176807A1 (en) 2019-02-27 2020-09-03 Vanderbilt University Methods of treating trigeminal nerve pain
CN110826145B (zh) * 2019-09-09 2020-08-28 西安工业大学 基于超启发式马氏链进化的汽车多参数运行工况设计方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2223792A1 (en) 1995-06-13 1997-01-03 The Salk Institute For Biological Studies Urocortin peptides
IL154102A0 (en) * 2000-08-04 2003-07-31 Res Dev Foundation Urocortin proteins and uses thereof
US20020082409A1 (en) 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
12 (8) 1077-1085.12 8.1998,1077-1085..
12 (8) 1077-1085.12 8.1998,1077-1085.. *
83 (12) 4510-4513.83 12.1998,4510-4513.
83 (12) 4510-4513.83 12.1998,4510-4513. *
Botti-Chiara
Boura-Alan-L-A
Chen-Airu
Kostich-Walter-A
Kostich-Walter-A;Chen-Airu;Sperle-Karen;Largent-Brian-L {a}.Molecular identification and analysis of a novel humancorticotropin-releasing factor (CRF) receptor: TheCRF2gamma receptor..Molecular-Endocrinology. Aug., 1998 *
Largent-Brian-L {a}.Molecular identification and analysis of a novel humancorticotropin-releasing factor (CRF) receptor: TheCRF2gamma receptor..Molecular-Endocrinology. Aug., 1998
Leitch-Ian-M {a}
Leitch-Ian-M {a};Boura-Alan-L-A;Botti-Chiara;Read-Mark-A;Walters-William-A-W;Smith-Roger.Vasodilator actions of urocortin and related peptides in thehuman perfused placenta in vitro..Journal-of-Clinical-Endocrinology-and-Metabolism. Dec., 1998 *
Read-Mark-A
Smith-Roger.Vasodilator actions of urocortin and related peptides in thehuman perfused placenta in vitro..Journal-of-Clinical-Endocrinology-and-Metabolism. Dec., 1998
Sperle-Karen
Walters-William-A-W

Also Published As

Publication number Publication date
CN1484650A (zh) 2004-03-24
US7223846B2 (en) 2007-05-29
KR20030074589A (ko) 2003-09-19
CA2418144C (en) 2013-06-18
CY1110424T1 (el) 2015-04-29
EP1305334A1 (en) 2003-05-02
IL154102A (en) 2010-12-30
US7638607B2 (en) 2009-12-29
US20020127221A1 (en) 2002-09-12
US8044025B2 (en) 2011-10-25
PT1305334E (pt) 2008-12-30
US20070191592A1 (en) 2007-08-16
US6838274B2 (en) 2005-01-04
AU2001284683B2 (en) 2006-04-27
DK1305334T3 (da) 2009-02-02
ATE408622T1 (de) 2008-10-15
JP4873825B2 (ja) 2012-02-08
DE60135850D1 (de) 2008-10-30
RU2003105897A (ru) 2005-01-20
US20050191650A1 (en) 2005-09-01
ES2313978T3 (es) 2009-03-16
EP1305334B1 (en) 2008-09-17
CA2418144A1 (en) 2002-02-14
EP1305334A4 (en) 2005-03-23
KR100879232B1 (ko) 2009-01-20
IL154102A0 (en) 2003-07-31
AU8468301A (en) 2002-02-18
WO2002012307A1 (en) 2002-02-14
RU2278871C2 (ru) 2006-06-27
US20100168021A1 (en) 2010-07-01
JP2004505640A (ja) 2004-02-26

Similar Documents

Publication Publication Date Title
US8044025B2 (en) Urocortin proteins and uses thereof
US8445425B2 (en) Urocortin-III and uses thereof
US6599718B1 (en) Growth hormone secretagogue related receptors and nucleic acids
US20120128695A1 (en) Teneurin c-terminal associated peptides (tcap) and methods and uses thereof
AU2001284683A1 (en) Urocortin proteins and uses thereof
AU2002306853A1 (en) Urocortin-III and uses thereof
NZ523803A (en) Human urocortin-related polypeptide (URP) and uses thereof to rreat a pathophysiological state, eg stress, anxiety and appetite dysfunction

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20040324

CI01 Publication of corrected invention patent application

Correction item: Rejection of patent application

Correct: Dismiss

False: Reject

Number: 31

Volume: 26

ERR Gazette correction

Free format text: CORRECT: PATENT APPLICATION REJECTION AFTER PUBLICATION; FROM: REJECTION TO: REJECTION OF REVOCATION

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121212

Termination date: 20190731

CF01 Termination of patent right due to non-payment of annual fee